Arvinas to present preclinical data on ARV-393, a BCL6 degrader, at the EHA meeting in Milan, June 2025.
Quiver AI Summary
Arvinas, Inc. announced that it will present new preclinical data on its investigational oral PROTAC BCL6 degrader, ARV-393, at the upcoming European Hematology Association (EHA) meeting in Milan from June 12-15, 2025. The studies highlight ARV-393's effectiveness as a single agent for treating nodal T-follicular helper cell lymphoma and transformed follicular lymphoma, as well as its potential in combination with small molecule inhibitors for diffuse large B-cell lymphoma. ARV-393 aims to address the challenges posed by the BCL6 protein, a critical factor in B-cell lymphomas, by promoting its degradation, which could impact treatment options for patients with relapsed or refractory non-Hodgkin lymphoma. The company, based in New Haven, Connecticut, continues to advance various investigational drugs using its targeted protein degradation platform.
Potential Positives
- Company to present promising preclinical data for ARV-393, an investigational drug targeting B-cell lymphomas, at the European Hematology Association meeting, which could increase visibility and credibility in the oncology community.
- ARV-393 aims to address the historically challenging targets associated with BCL6, potentially offering new treatment options for patients with relapsed/refractory non-Hodgkin lymphoma.
- The ongoing Phase 1 clinical trial for ARV-393 indicates active progress towards clinical application, which is crucial for attracting investors and partners interested in innovative cancer therapies.
Potential Negatives
- Potential risk that the clinical development of ARV-393 may not proceed as planned, which could impact investor confidence and future funding.
- Forward-looking statements indicate significant uncertainties regarding the success of ongoing clinical trials, implying that actual results may substantially differ from expectations.
- Concerns over the company's ability to maintain sufficient cash flow to support ongoing operations and capital requirements, which could jeopardize project timelines.
FAQ
What is ARV-393?
ARV-393 is an investigational oral PROTAC degrader targeting the BCL6 protein, which drives various B-cell lymphomas.
When will Arvinas present new data for ARV-393?
New preclinical data for ARV-393 will be presented at the EHA meeting from June 12-15, 2025.
What types of lymphoma is ARV-393 being studied for?
ARV-393 is being studied as a treatment for nodal T-follicular helper cell lymphoma and transformed follicular lymphoma.
Where is Arvinas headquartered?
Arvinas is headquartered in New Haven, Connecticut.
How does ARV-393 work?
ARV-393 aims to degrade the BCL6 protein, potentially overcoming its traditional undruggable nature in B-cell lymphomas.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ARVN Insider Trading Activity
$ARVN insiders have traded $ARVN stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $ARVN stock by insiders over the last 6 months:
- JOHN G HOUSTON (President and CEO) has made 0 purchases and 2 sales selling 31,338 shares for an estimated $523,880.
- IAN TAYLOR (President, R&D) has made 0 purchases and 2 sales selling 9,020 shares for an estimated $150,752.
- NOAH BERKOWITZ (Chief Medical Officer) sold 8,658 shares for an estimated $74,372
- ANGELA M CACACE (Chief Scientific Officer) has made 0 purchases and 2 sales selling 4,207 shares for an estimated $70,238.
- DAVID K LOOMIS (Chief Accounting Officer) sold 1,214 shares for an estimated $20,334
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ARVN Hedge Fund Activity
We have seen 128 institutional investors add shares of $ARVN stock to their portfolio, and 114 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC removed 6,726,491 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $47,219,966
- BELLEVUE GROUP AG removed 2,389,600 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $16,774,991
- PARADIGM BIOCAPITAL ADVISORS LP removed 2,339,961 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $44,857,052
- ALYESKA INVESTMENT GROUP, L.P. added 1,800,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $12,636,000
- ARROWMARK COLORADO HOLDINGS LLC removed 1,776,555 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,471,416
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,660,130 shares (-75.2%) from their portfolio in Q1 2025, for an estimated $11,654,112
- UBS GROUP AG removed 1,563,150 shares (-76.7%) from their portfolio in Q1 2025, for an estimated $10,973,313
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ARVN Analyst Ratings
Wall Street analysts have issued reports on $ARVN in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 05/02/2025
- BMO Capital issued a "Outperform" rating on 03/12/2025
- Wells Fargo issued a "Overweight" rating on 03/12/2025
To track analyst ratings and price targets for $ARVN, check out Quiver Quantitative's $ARVN forecast page.
$ARVN Price Targets
Multiple analysts have issued price targets for $ARVN recently. We have seen 5 analysts offer price targets for $ARVN in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- Srikripa Devarakonda from Truist Financial set a target price of $11.0 on 05/05/2025
- Jeet Mukherjee from BTIG set a target price of $16.0 on 05/02/2025
- An analyst from Morgan Stanley set a target price of $12.0 on 03/13/2025
- Etzer Darout from BMO Capital set a target price of $20.0 on 03/12/2025
- Derek Archila from Wells Fargo set a target price of $26.0 on 03/12/2025
Full Release
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma –
NEW HAVEN, Conn., June 05, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that new preclinical data for ARV-393 will be presented at the European Hematology Association (EHA) meeting, June 12-15, 2025 in Milan, Italy. ARV-393 is Arvinas’ investigational orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.
Presentation details are as follows:
Poster Title: ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular Lymphoma
Abstract:
PF1000
Session Title:
Lymphoma biology & translational research
Date:
Thursday, June 13, 2025
Time:
6:30-7:30 p.m. CEST
The full abstract can be accessed via the EHA 2025 online interactive program .
About ARV-393
ARV-393 is an investigational orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas. The BCL6 protein facilitates B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage response. PROTAC-mediated degradation has the potential to address the traditional undruggable nature of BCL6. ARV-393 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory non-Hodgkin lymphoma.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit
www.arvinas.com
and connect on
LinkedIn
and
X
.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential for PROTAC-mediated degradation to address the traditional undruggable nature of BCL6. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “look forward,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-393, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
[email protected]
Media:
Kirsten Owens
+1 (203) 584-0307
[email protected]
